Elevation of antibody against Epstein-Barr virus genes BRLF1 and BZLF1 in nasopharyngeal carcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 126, Issue 2, 2000, Pages 69-73

  Yoshizaki, Tomokazu ^a   Miwa, Hiroko ^a   Takeshita, Hajime ^a   Sato, Hiroshi ^a   Furukawa, Mitsuru ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

BRLF1; BZLF1; Epstein Barr virus; Nasopharyngeal carcinoma; Serology

Indexed keywords

ANTIBODY TITER; ARTICLE; CANCER SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; HEAD AND NECK CANCER; IMMEDIATE EARLY GENE; IMMUNOBLOTTING; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; REMISSION; SERODIAGNOSIS; VIRUS GENE;

CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; DNA-BINDING PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENES, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; IMMEDIATE-EARLY PROTEINS; IMMUNOGLOBULINS; NASOPHARYNGEAL NEOPLASMS; TRANS-ACTIVATORS; VIRAL PROTEINS;

EID: 0033959966     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Chevalier-Greco A, Manet E, Chavrier P, Mosnier C, Daillie J, Sergeant A (1986) Both Epstein-Barr(EBV)-encoded transacting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter. EMBO J 5:3243-3249
2. Cochet C, Martel-Renoir D, Grunewald V, Bosq J, Cochet G, Schwaab G, Bernaudin J, Joab I (1993) Expression of EpsteinBarr virus immediate early gene, BZLF1, in nasopharyngeal carcinoma tumor cells. Virology 197:358-365
3. Countrymann J, Jenson H, Seibl R, Wolf H, Miller G (1987) Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. Virology 61:3672-3679
4. Cox M, Leahy J, Hardwick JM (1990) An enhancer within the divergent promoter of Epstein-Barr virus responds synergistically to the R and Z transactivators. J Virol 64:313-321
5. Hausen zur H, Schulte-Holthausen I, Klein G, Henle W, Henle G, Clifford P, Santesson L (1970) EBV-DNA in biopsies of Burkitt's tumors and anaplastic carcinomas of the nasopharynx. Nature 228:1056-1058
6. Henle W, Henle G, Zajac BA, Pearson C, Waubke R, Scriba M (1970) Differential reactivity of human serum with early antigens induced by Epstein-Barr virus. Science 169:188-190
7. Henle W, Ho JC, Henle G, Kwan HC (1973) Antibodies to Epstein-Barr related antigen in nasopharyngeal carcinoma. Comparison of active cases and long term survivors. J Natl Cancer Inst 51:361-369
8. Joab I, Nicolas J, Schwaab G, de-The G, Clausse B, Perricaudet M, Zeng Y (1991) Detection of anti-Epstein-Barr-virus transactivator (ZEBRA) antibodies in sera from patients with nasopharyngeal carcinoma. Int J Cancer 48:647-649
9. Liu C, Sista ND, Pagano JS (1996) Activation of the Epstein-Barr virus DNA polymerase promoter by the BRLF1 immediateearly protein is mediated through USF and E2F. J Virol 70:2545-2455
10. Lynn TC, Tu SM, Kawamura A (1985) Long-term follow-up of IgG and IgA antibodies against viral capsid antigens of Epstein-Barr virus in nasopharyngeal carcinoma. J Laryngol Otol 99:567-572
11. Manet E, Gruffat H, Biemont MC, Moreno N, Chambard P, Giot JF, Sergeant A (1989) Epstein-Barr virus bicistronic mRNAs generated by facultative splicing code for two transcriptional transactivators. EMBO J 8:1819-1826
12. Manet E, Allera C, Gruffat H, Mikaelian I, Rigolet A, Sergeant A (1993) The acidic activation domain of the Epstein-Barr virus transcription factor R interacts in vitro with both TBP and TFIIB and is cell-specifically potentiated by a proline-rich region. Gene Expr 3:49-59
13. Martel-Renoir D, Grunewald V, Touitou R, Schwaab G, Joab I (1995) Qualitative analysis of Epstein-Barr virus lytic genes in nasopharyngeal carcinoma biopsies. J Gen Virol 76:1401-1408
14. Mathew A, Cheng HM, Sam CK, Joab I, Prasad U, Cochet C (1994) A high incidence of serum IgG antibodies to the Epstein-Barr virus replication activator protein in nasopharyngeal carcinoma. Cancer Immunol Immunother 38:68-70
15. Ragoczy T, Heston L, Miller G (1998) The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J Virol 72:7978-7984
16. Sato H, Takeshita H, Furukawa M, Seiki M (1992) Epstein-Barr virus BZLF1 transactivator is a negative regulator of Jun. J Virol 66:4732-4736
17. Takada K, Shimizu N, Sakuma S, Ono Y (1986) trans activation of the latent Epstein-Barr virus(EBV) genome after transfection of the EBV DNA fragment. J Virol 57:1016-1022
18. Yip TC, Ngan KC, Lau WH, Poon YF, Joab I, Cochet C, Cheng, AK (1994) A Possible prognostic role of immunoglobulin-G antibody against recombinant Epstein-Barr virus BZLF1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma. Cancer 74:2414-2424
19. Zalani S, Holley-Guthrie E, Kenney S (1996) Epstein-Barr viral latency is disrupted by immediate-early BRLF1 protein through a cell-specific mechanism. Proc Natl Acad Sci USA 93:9194-9199